Shelton, Connecticut headquartered Cara Therapeutics Inc.'s stock finished Monday's session 7.98% higher at $11.10. A total volume of 1.49 million shares was traded, which was above their three months average volume of 1.36 million shares. The Company's shares have advanced 16.72% in the past month, 28.03% over the previous three months, and 19.48% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 19.77% and 58.07%, respectively. Furthermore, shares of Cara Therapeutics, which focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the US, have a Relative Strength Index (RSI) of 65.73.
On November 29th, 2016, Cara Therapeutics announced that it has completed patient enrollment for the multi-dose phase of its adaptive Phase 2/3 trial of I.V. CR845 in dialysis patients suffering from moderate-to-severe uremic pruritus (UP). The Company noted that UP is an intractable systemic itch condition in patients with chronic kidney disease, for which there are no approved therapies in the US. Your complete research report on CARA can be retrieved for free at:
Shares in Durham, North Carolina-based Heat Biologics Inc. ended at $0.98, up 3.16% from the last trading session. The stock recorded a trading volume of 1.25 million shares. The Company's shares have gained 13.95% since the start of this year. The stock is trading 5.43% below its 200-day moving average. Moreover, shares of Heat Biologics, which focuses on the development and commercialization of novel allogeneic off-the-shelf cellular therapeutic vaccines for a range of cancers and infectious diseases in the US, have an RSI of 48.70.
On January 04th, 2017, Heat Biologics announced the appointment of Jeff Hutchins, Ph.D., as Chief Scientific Officer and Senior Vice President of Preclinical Development. Dr. Hutchins will be overseeing Heat's research efforts, bringing over 24 years of research and clinical development experience from both large pharmaceutical and biotechnology companies. Most recently, Dr. Hutchins served as Vice President of Preclinical Research for Peregrine Pharmaceuticals, Inc. Dr. Hutchins was responsible for building out the research program for Peregrine's lead product candidate, bavituximab, a chimeric monoclonal antibody designed to target phosphatidylserine. Currently in clinical development, bavituximab is being evaluated in combination through Peregrine-funded trials and collaborations, including AstraZeneca and the National Comprehensive Cancer Network. HTBX free report is just a click away at:
Washington, the District of Columbia headquartered Vanda Pharmaceuticals Inc.'s stock ended yesterday's session 4.23% lower at $14.70. A total volume of 1.06 million shares was traded, which was higher than their three months average volume of 554,130 shares. The Company's shares are trading 13.25% above their 200-day moving average. Additionally, shares of Vanda Pharmaceuticals, which focuses on the development and commercialization of products for the treatment of central nervous system disorders, have an RSI of 38.06.
On January 09th, 2017, Vanda Pharmaceuticals announced preliminary unaudited financial results for Q4 2016 and FY16 and its financial guidance for 2017. Vanda expects to report FY16 total net product sales from HETLIOZ® and Fanapt® of approximately $146 million. The Company's HETLIOZ® net product sales for 2016 are expected to be approximately $72 million. Vanda ended 2016 with approximately $141 million in cash, cash equivalents and marketable securities. For FY17, Vanda expects net product sales from both HETLIOZ® and Fanapt® of between $165 million and $175 million; HETLIOZ® net product sales to be between $88 million and $93 million. Cash is expected to decrease by less than $20 million during 2017. Sign up for your complimentary research report on VNDA at:
At the close on Monday, shares in The Woodlands, Texas-based Opexa Therapeutics Inc. recorded a trading volume of 412,375 shares. The stock finished 2.26% lower at $0.91. The Company's shares have gained 2.22% in the last one month and are trading below their 50-day moving average by 6.03%. Furthermore, shares of Opexa Therapeutics, which develops personalized immunotherapy to treat multiple sclerosis (MS) and other autoimmune diseases based on its proprietary T-cell technology, have an RSI of 50.68. Register for free on Stock-Callers.com and download the latest research report on OPXA at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA